CCR5 and Cancer

Our CMO Dr. Richard Pestell, MD, PhD, MB, BS, FACP, FRACP, FAAAS, MBA, is a world renowned oncologist. Dr. Pestell founded ProstaGene (recently acquired by CytoDyn), to develop CCR5 technology in cancer indications with focus on metastasis of many types of cancer. Dr. Pestell previously served as Director of two National Cancer Institute Cancer Centers that focused on innovation for novel cancer treatments and trials.

Dr. Pestell has published preclinical studies that provide support for CCR5’s role in cancer and cancer metastasis. These studies demonstrate CCR5 inhibitors’ ability to effectively block breast and prostate cancer spread and to block human breast cancer metastasis. In preclinical studies CCR5 inhibitors blocked prostate cancer metastasis to the bones, the brain and other organs with high effectiveness. You can learn more about CCR5’s role in cancer and Dr. Pestell’s research by viewing the videos and reading the articles below.

Video: Serious Science: Cancer Metastasis Promotion by CCR5 Receptor – Richard Pestell

Video: Serious Science: Cell Cycle and Cancer – Richard Pestell

Article: CCR5 Antagonist Blocks Metastasis of Basal Breast Cancer Cells

Article: CCR5 Receptor Antagonists Block Metastasis to Bone of v-Src Oncogene-Transformed Metastatic Prostate Cancer Cell Lines

Article: The CCL5/CCR5 axis promotes metastasis in basal breast cancer

Video: Richard Pestell at TEDxOccidental College: Is good health a choice?

Article: CCR5 Governs DNA Damage Repair and Breast Cancer Stem Cell Expansion